Enliven Therapeutics, Inc.
Helen Louise Collins (CHIEF MEDICAL OFFICER) sells ELVN shares
About this filing
Enliven Therapeutics, Inc. (ELVN) filed Form 4 (insider transaction) with the SEC on Oct 21, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Helen Louise Collins · CHIEF MEDICAL OFFICER
Rule 10b5-1 plan · adopted Oct 19, 2025
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Oct 19, 2026 | M · exercise or conversion of a derivativeFootnotes F1, F2 | +5,000 | $2.48 | $12,400.00 | 30,000 | Direct |
| Oct 19, 2026 | S · open-market saleFootnotes F1, F3, F4 | −5,000 | $38.47 | $192,342.00 | 25,000 | Direct |
| Oct 19, 2026 | M · exercise or conversion of a derivativeStock Option (right to buy)Footnotes F1, F5 | −5,000 | $0.00 | $0.00 | 101,268 | Direct |
Footnotes
- F1 The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.
- F2 Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- F3 This transaction was executed in multiple trades at prices ranging from $37.785 to $38.75. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F4 These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- F5 All of the shares subject to this option are fully vested and exercisable as of the date hereof.
More ELVN filings
- 10-Q
Filed Nov 5, 2026
- 8-K
Filed Nov 5, 2026
- 4
Filed Nov 3, 2026
- SC 13G/A
Filed Oct 27, 2026
- 4
Filed Oct 21, 2026
- 144
Filed Oct 19, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.